STAT+: Questions about the FDA’s ‘radical transparency’ efforts
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about the FDA’s move to release a limited batch of complete response letters.
FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy
From my colleague Adam Feuerstein: The Food and Drug Administration rejected a marketing application from Capricor Therapeutics seeking clearance for a cell therapy to treat Duchenne muscular dystrophy, the company said this morning.
Meghana Keshavan
Go to statnews